OncoMatch/Clinical Trials/NCT04771130
A Study of BGB-11417 in Participants With Myeloid Malignancies
Is NCT04771130 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for acute myeloid leukemia.
Treatment: BGB-11417 · Azacitidine · Posaconazole · BGB-11417 · BGB-11417 — The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Biomarker criteria
Excluded: ABL1 fusion
Excluded: BCR fusion
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: B-cell lymphoma-2 inhibitor
Prior therapy with a B-cell lymphoma-2 inhibitor
Lab requirements
Kidney function
creatinine clearance ≥ 50 ml/min (or between 30 and 49 ml/min in unfit aml cohort)
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope National Medical Center · Duarte, California
- Tampa General Hospital · Tampa, Florida
- Upmc Hillman Cancer Center(Univ of Pittsburgh) · Pittsburgh, Pennsylvania
- Md Anderson Cancer Center · Houston, Texas
- Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify